CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Panitumumabdrug
Likely dose
Panitumumab 9 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01202409
NCT01202409Phase 2Completed
CompareCT.gov

Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater

M.D. Anderson Cancer Center·interventional·Posted Sep 15, 2010·Updated Feb 21, 2020

In Brief

A Phase 2 clinical trial evaluating Panitumumab for Gastrointestinal Cancer. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if panitumumab can help to control advanced cancer of the small bowel or ampulla of Vater. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Cancer
CountriesUnited States
CollaboratorsAmgen

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 15, 2010
Enrollment StartNov 2, 2010
Primary CompletionJul 3, 2018
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 15.8 years ago

Interventions

Panitumumabdrug

Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.